New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...
Soluble TAM receptors (sTAMs) could serve as biomarkers for RA, indicating disease activity, severity, and prognosis, though standardized detection methods are needed. TAM receptors could emerge as ...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
13d
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Phase 3 Study initiating in First Quarter of 2026Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.
The authors identify the Bearded-type small protein E(spl)m4 as a physical and genetic interactor of TRAF4 in the Drosophila wing disc. These valuable findings with potential biomedical relevance are, ...
Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic ...
Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback